Although participants in this trial received a personalized dose of follitropin delta by taking into account their AMH (>35 pmol/L) and body weight (32 kg/m2), evidence in the field describes that women suffering from PCOS and polycystic ovaries represented a risk group for the overweight and/or obese [95]; the selection of an optimal gonadotropin dose is, therefore, a real challenge due to a negative correlation between the serum FSH level and body weight [96], low variability of serum FSH, and poor ovarian response [96,97]. Here, BRD2 is linked to polycystic ovary syndrome.